SMARCB1 and epithelioid sarcoma: In the largest series published on INI1-negative ES patients suffering advanced disease, which was derived from a multicentric, international retrospective study aimed at investigating the activity of the medical agents formally approved for treatment of this disease, drug efficacy looked to be limited, especially in terms of the duration of response.